Session

Back to Programme Overview

Prostate cancer progression, epithelial to mesenchymal transition and nuclear receptors

Poster Session 11

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chairs:
     A.S. Bjartell, Malmö (SE)
     G. Carbone, Bellinzona (CH)
     M. Puhr, Innsbruck (AT)
  • Aims and objectives of this session

    Cellular events during prostate cancer progression are controlled by transcription factors, miRNA, and nuclear receptors. Several contributions highlight the role of miRNA in different prostate cell types and show causal relationships with prostate cancer progression and stemness. These novel regulatory networks will be discussed in the session.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 145
Functional high-throughput screening and expression analysis identify microRNAs sharing the AAGUGC seed sequence as key regulators of epithelial-mesenchymal transition in prostate cancer

By: Rao S.1, Howarth A.2, Kratschmer P.1, Snaith A.1, Haire A.1, Yapp C.1, Ebner D.2, Hamdy F.1, Edwards C.1

Institutes: 1University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 2University of Oxford, Nuffield Dept. of Medicine, Oxford, United Kingdom

* 146
MicroRNA-424 promotes STAT3 activation and prostate cancer progression

By: Dallavalle C.1, Albino D.1, Civenni G.1, Merulla J.1, Mello-Grand M.2, Ostano P.2, Losa M.1, Thalmann G.3, Chiorino G.2, Catapano C.1, Carbone G.1

Institutes: 1IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, 2Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy, 3University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland

147
Characterization and personalized treatment response in primary and metastatic prostate canceroids

By: Karkampouna S.1, La Manna F.2, Zoni E.1, Beimers L.3, Kloen P.4, Wetterwald A.1, Grosjean J.1, Klima I.1, Cecchini M.1, Spahn M.5, Thalmann G.5, Kruithof-De Julio M.1

Institutes: 1Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, 2Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, 3Slotervaart Medical Centre, Dept. of Orthopaedic Surgery, Amsterdam, The Netherlands, 4Academic Medical Centre, Dept. of Orthopaedic Trauma Surgery, Amsterdam, The Netherlands, 5University Hospital Bern, Dept. of Urology, Bern, Switzerland

* 148
MCAM supports the aggressive phenotype in human prostate cancer

By: Zoni E.1, Astrologo L.1, Melsen J.2, Klima I.1, Grosjean J.1, Van Der Plujim G.2, Cecchini M.1, Kruithof-De Julio M.1, Thalmann G.3

Institutes: 1Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, 2Leiden University Medical Center, Urology Research Laboratory, Leiden, The Netherlands, 3University Hospital Bern, Dept. of Urology, Bern, Switzerland

149
Epigenetic mechanisms and therapeutic opportunities in metastatic castration resistant prostate cancer

By: Ruggero K.1, Giacobbe A.2, Mitrofanova A.3, Calvet A.1, Palomero L.1, Pujana M.A.1, Califano A.4, Abate-Shen C.2, Aytes A.1

Institutes: 1Idibell, Dept. of Procure, Ico, Barcelona, Spain, 2Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medica, Dept. of Urology, Medicine, Systems Biology, and Pathology and Cell Biology, New York, United States of America, 3Rutgers, Dept. of Health Informatics, Newark, United States of America, 4Center for Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Co, Dept. of Systems Biology, Biomedical Informatics, and Biochemistry and Molecular Biophysics, New York, United States of America

150
EMT status within M1 diagnostic prostate biopsies correlate with stem like phenotype and loss of AR signalling

By: Hiew K.1, Bokobza S.2, Hart C.3, Elliott T.4, Smith N.2, Brown M.3, Clarke N.5

Institutes: 1Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, 2AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, 3The University of Manchester, Genito Urinary Cancer Research Group, Division of Molecular & Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, 4Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, 5Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

151
Steroid hormone receptors are differently expressed in prostate cancer depending on Gleason grade and presence of disease recurrence

By: Gevaert T.1, Vandenbroeck T.1, Van Poppel H.1, Claessens F.2, Salmon I.3, Rorive S.3, Decaestecker C.4, Van Eycke Y.4, De Ridder D.1, Joniau S.1

Institutes: 1UZ Leuven, Dept. of Urology, Leuven, Belgium, 2KU Leuven, Dept. of Molecular and Cellular Medicine, Leuven, Belgium, 3Université Libre de Bruxelles, Dept. of Pathology, Brussels, Belgium, 4Université Libre de Bruxelles, DIAPath – Center for Microscopy and Molecular Imaging, Gosselies, Belgium

152
Characterizing androgen receptor blockade- and metabolic stress-induced tunneling nanotube formation supporting stress adaptivity in prostate cancer

By: Kretschmer A.1, Zhang F.1, Tse C.1, Leachman L.1, Gleave A.1, Somasekharan S.P.1, Sorensen P.2, Gleave M.1

Institutes: 1Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, 2BC Cancer Research Centre, Dept. of Pathology, Vancouver, Canada

153
Neoadjuvant hormonal therapies induce the expression of AR transcript variants

By: Tammela T.1, Kallio H.2, Annala M.2, Brofeldt A.2, Hieta R.2, Kivinummi K.2, Nykter M.2, Lilja H.2, Bova G.2, Visakorpi T.2

Institutes: 1Tampere University Hospital, Dept. of Surgery, Tampere, Finland, 2University of Tampere, Biomeditech, Tampere, Finland

154
Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling

By: Fukumori T.1, Dondoo T-O.1, Daizumoto K.2, Fukawa T.2, Yamamoto Y.2, Yamaguchi K.2, Takahashi M.2, Kanayama H-O.2

Institutes: 1Tokushima University, Dept. Of Urology, Tokushima, Japan, 2Tokushima University, Dept. of Urology, Tokushima, Japan

155
Effect and mechanism of TR4 nuclear receptor on invasion of CD133+ prostate cancer cells

By: Shan Y.X.

Institutes: Second Affiliated Hospital Of Soochow University, Suzhou, China, Dept. of Urology, Suzhou, China

* 156
Semaphorin/plexin signalling promotes trafficking of glucocorticoid receptor and androgen receptor to the nucleus

By: Magali Williamson M.

Institutes: Kings College London, Randall Division, London, United Kingdom

Epithelial to mesenchymal transition in prostate cancer
 G. Carbone, Bellinzona (CH)